Glioblastoma remains one of the most aggressive brain cancers, with limited treatment options beyond surgery, radiation, and chemotherapy. Personalized immunotherapy represents a model shift, matching individual tumor characteristics to targeted protocols. Key Takeaways Select cancer centers offer personalized immunotherapy through clinical trials and specialized programs, with eligibility determined by thorough biomarker testing rather than universal availability Major proto

Glioblastoma remains the most aggressive primary brain tumor in adults, with median survival of 14-16 months under standard care, yet personalized immunotherapy has emerged as a transformative treatment approach achieving significantly improved outcomes at specialized cancer centers. TL;DR Yes, cancer centers including Pi Cancer Care now offer personalized immunotherapy for glioblastoma patients through dendritic cell therapy, CAR-T cell protocols, and tumor-specific vaccine